COVID-19 Treatment (FM203) Selection of Preclinical Test Support Project for Infectious Diseases

Glaucoma Treatment (FM101) Selection of the National New Drug Development Project (KDDF) New Drug Clinical Development Research Project

The Ministry of SMEs and Startups selected a 'preliminary unicorn'

Evaluation A and A grades of technology growth companies (Korea Industrial Technology Evaluation Management Agency, Nice Evaluation Information)

FM101 Approves Phase 2 IND For NASH Indication (Europe)

[Ascentage Pharma (Hong Kong-listed corporation)] NASH Joint Research Agreement Signed

FM101 Approves Phase 2 IND For Glaucoma Indication (Australia)

FM101, designated by the U.S. Food and Drug Administration (FDA) as a rare drug for 'primary bile ductitis'

PPre-IPO investment attraction of 7.2 billion completed (Raguna Investment, Korea Asset Investment & Securities, etc.)

The Ministry of Science and ICT selected a project to develop an innovative new drug pipeline

• - Metabolic anticancer drugs for the development of innovative new drug pipelines (2 years, 2 billion won in project
• - Targeted anticancer drugs for the development of innovative new drug pipelines (2 years, 3 billion won in project cost)

[Dongkuk University, Korea Biotechnology Research Institute] Signed a contract for a metabolic anticancer drug, License-In

Future Medicine Establishes Australian Corporation

FM101, License-Out (Domestic and China) to HK Innoen (formerly CJ Healthcare Co., Ltd.)

Selection of non-clinical tasks by the Ministry of Health and Welfare: Non-clinical support for COVID-19 treatments (1 year, project cost KRW 640 million)

[SNU Industry-Academic Cooperation Group] Know-how related to immuno-cancer drugs signed a license-in contract

Ministry of Health and Welfare's Health and Medical Technology R&D Project Selection: NASH Treatment Development (2 years, project cost KRW 2.1 billion)

Pre-IPO attracting 6.5 billion investment (Korea Investment & Securities, Hanwha Investment & Securities, HK Innoen, BNK Venture Investment)